Drug intelligence / Profile preview

TKP-AII-09

Development stage: Unknown
Lead developer: TheraCea Pharma
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

TKP-AII-09 is an 18F-labeled peptide radiopharmaceutical developed by TheraCea Pharma for the diagnostic imaging of breast cancer. It functions as a positron emission tomography (PET) tracer, utilizing the radioactive isotope fluorine-18 to provide high-resolution imaging. While the specific biological target of the peptide has not been publicly disclosed by the developer, the agent is designed to selectively bind to biomarkers associated with breast cancer cells, facilitating the detection, staging, and monitoring of the disease. The drug is currently in clinical development, progressing through Phase 2 trials.

Beyond the preview

Go deeper on TKP-AII-09.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TKP-AII-09.

Explore the full profile